Early reduction in NT-proBNP is associated with lower risk of mortality and heart failure readmissions up to LVEF 64%, but not in patients with LVEF ≥65%.
Does the prognostic significance of early NT-proBNP changes vary across LVEF categories in patients hospitalized for acute heart failure?
Early NT-proBNP reduction during AHF hospitalization is a strong prognostic marker for patients with LVEF up to 64%, but loses its predictive value in those with supranormal LVEF (≥65%).
Absolute Event Rate: 0% vs 0%
Abstract Aims Reductions in NT-proBNP during hospitalization for acute heart failure (AHF) are linked with improved outcomes. Whether this association holds along the entire spectrum of left ventricular ejection fraction (LVEF), particularly in patients with supranormal LVEF (≥65%), remains unclear. We aimed to evaluate whether the prognostic significance of early NT-proBNP changes varies across LVEF categories. Methods and results We included 3,276 consecutive patients hospitalized for AHF across three tertiary centers. NT-proBNP was measured at admission and within 48–72 hours. The relative change (ΔNT-proBNP) was calculated, and patients were stratified into four LVEF categories: ≤40%, 41–49%, 50–64%, and ≥65%. Primary outcomes were all-cause mortality, cardiovascular death, and recurrent HF hospitalizations, analyzed using multivariable Cox and negative binomial models. The proportion of patients with LVEF ≤40%, 41–49%, 50–64%, and ≥65% was 36.3%, 13.3%, 31.5%, and 19.9%, respectively. Median ΔNT-proBNP was 8.8% (-38.7 to 22.9), and 32.3% of patients exhibited a decline of ≥30%. Over a median follow-up of 1.65 years (0.40-2.66), 1,420 deaths (43.4%) and 1,979 HF-readmissions occurred in 1,045 patients. After multivariate analyses, a significant interaction was found between ΔNT-proBNP and LVEF category for all outcomes (p for interaction 0.05). Greater NT-proBNP reduction was independently associated with lower risk of all outcomes, but this association weakened at higher LVEF categories and was no longer evident in patients with LVEF ≥65%. Conclusions Early NT-proBNP reduction is a robust prognostic marker in AHF with LVEF up to 64%. Its utility is limited in patients with supranormal LVEF.
Núñez-Marín et al. (Thu,) reported a other. Early reduction in NT-proBNP is associated with lower risk of mortality and heart failure readmissions up to LVEF 64%, but not in patients with LVEF ≥65%.